Earlier this month the Association for Accessible Medicines (AAM) and its Biosimilars Council hosted the second annual GRx+Biosims Conference for more than 600 attendees from around the world. The jam-packed three-day event featured notable speakers from the U.S. Food and Drug Administration (FDA), industry, payer and patient advocacy groups to discuss how best to increase patient access to safe, effective and competitively priced generics and biosimilars.
GRx+Biosims kicked off with keynotes from FDA leaders Anna Abram, Deputy Commissioner for Policy, Legislation and International Affairs and Dr. Sarah Yim, Acting Director of the Therapeutic Biologics and Biosimilars Office. Both provided updates from the agency on regulatory issues related to the generics and biosimilars industries and underscored their strong support for industry efforts to increase the availability of generic and biosimilar medicines for America’s patients. Each emphasized the FDA’s desire to continue to work closely with industry stakeholders to advance treatment options.